Who is sponsoring NCT06231238?

NCT06231238 is sponsored by King's College London.

What drugs are being tested in NCT06231238?

Interventions in NCT06231238: Balance Acceptance and Commitment Therapy.

What condition does NCT06231238 study?

NCT06231238 studies Post-COVID-19 Syndrome, Long COVID.

Is NCT06231238 still recruiting?

NCT06231238 is currently active, enrolled. Last updated 11 February 2026.

Last reviewed 2026-02-11 · How we verify

NCT06231238: BalanceACT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Balance Acceptance and Commitment Therapy for Long COVID

Active, enrolled NA Last updated 11 February 2026

What this trial tests

NA trial testing Balance Acceptance and Commitment Therapy in Post-COVID-19 Syndrome in 196 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

4 June 2024

Primary endpoint
14 April 2026

1 June 2026

Quick facts

Lead sponsor	King's College London
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	196
Start date	4 June 2024
Primary completion	14 April 2026
Estimated completion	1 June 2026
Sites	1 location across United Kingdom

Drugs / interventions tested

Balance Acceptance and Commitment Therapy

Conditions studied

Post-COVID-19 Syndrome — all drugs for Post-COVID-19 Syndrome →
Long COVID — all drugs for Long COVID →

Sponsor

King's College London

Who can join

18 and older, any sex, with Post-COVID-19 Syndrome or Long COVID. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomised controlled trial aims to investigate the efficacy of a psychological intervention for long COVID (LC) / post-COVID-19 syndrome (PCS) called Balance Acceptance and Commitment Therapy (Balance ACT). The primary objective of this trial is to investigate whether Balance-ACT improves quality of life over treatment as usual (i.e., self-help leaflet) in people with PCS/LC.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Applicability and adaptation of cognitive behavior therapy for long COVID neuropsychiatric symptoms: a review with insights from ME/CFS.
Takamatsu N, Kuga H. · · 2025 · cited 1× · PMID 41073921 · DOI 10.1186/s12879-025-11754-0

Verify or expand the search:

Other King's College London trials

Trials by the same sponsor.

NCT07357064 — Professional Decision Making in Childbirth. · not yet recruiting
NCT07341087 — Skin Inflammation in Perimenopause: A Probiotic Intervention Proof of Concept Trial · NA · recruiting
NCT07228962 — Cutaneous Biomarkers in Atopic Eczema Using a Non-Invasive Micro-Suction Device in Babies · not yet recruiting
NCT07365722 — Comparison of Two Non-surgical Procedure to Manage Gum Disease Around Implants. · NA · not yet recruiting
NCT07378488 — Dance/Movement Therapy for Functional Neurological Disorder · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06231238 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by King's College London
Last refreshed: 11 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06231238.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing